EGFR and metastatic colorectal cancer: The OPUS study (Van Cutsem et al., 2011) is an open-label, randomized, multicenter phase II study, which included 337 newly treated mCRC patients with EGFR-expressing metastatic colorectal cancer who were randomized to receive FOLFIRI alone or combined with cetuximab.